August 2016

New Product - Sylvant

Sylvant (siltuximab) is a chimeric (human murine) immunoglobulin G1k (IgG1k) monoclonal antibody against human Interleukin‑6 (IL-6) produced in a Chinese hamster ovary (CHO) cell line. Siltuximab prevents the binding of human IL‑6 to both soluble and membrane bound IL‑6 receptors (IL‑6R), thus inhibiting the formation of the hexameric signalling complex with gp130 on the cell surface. Overproduction of IL-6 has been hypothesised to play a central role in driving plasma cell proliferation and systemic manifestations in patients with Castleman’s disease. Sylvant is indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus‑8 (HHV‑8) negative. Sylvant is available as a 100 mg and 400 mg powder for infusion in a single use glass vial in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au